[Correspondence] Distinct representation of muscle weakness in QMG and MG-ADL

We read the findings of James Howard and colleagues with interest.1 Their phase 3, randomised, double-blind, placebo-controlled multicentre study investigated the effect of eculizumab in patients with anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis. Notably, Howard and colleagues showed an apparent discrepancy between the primary (Myasthenia Gravis Activities of Daily Living; MG-ADL) and secondary (Quantitative Myasthenia Gravis test; QMG) endpoints. The primary endpoint, the change from baseline to week 26 in MG-ADL total score, did not significantly differ between the eculizumab-treated and placebo groups (p=0 ·0698).

Source: Lancet Neurology - February 14, 2018 Category: Neurology Authors: Robert Henri Pasquale de Meel, Jan J G M Verschuuren, Martijn R Tannemaat Tags: Correspondence Source Type: research